Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 17/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 16/20 | 0.51 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14154369 | 1.00 | ADK (0.52) | ADKADORA2APRMT5WDR77METTL3 | |
| SCHEMBL19632932 | 0.89 | ADK (0.54) | ADKADORA2APRMT5WDR77METTL3 | |
| SCHEMBL19636420 | 0.89 | ADK (0.54) | ADKADORA2APRMT5WDR77METTL3 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL14628542 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL15093204 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL731022 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL18661674 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL14640071 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL13055908 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL14081715 | 0.88 | ADORA2A (0.67) | ADKADORA2APRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| WO-2014058801-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083413-A1 | 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION | SLC28A2, SLC28A1, SLC29A2 | ADK 396/4885ADORA2A 300/4885PRMT5 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.